518 related articles for article (PubMed ID: 25776192)
21. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
22. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Wang ES
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
[TBL] [Abstract][Full Text] [Related]
23. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
[TBL] [Abstract][Full Text] [Related]
24. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Fiedler W; Kayser S; Kebenko M; Janning M; Krauter J; Schittenhelm M; Götze K; Weber D; Göhring G; Teleanu V; Thol F; Heuser M; Döhner K; Ganser A; Döhner H; Schlenk RF
Br J Haematol; 2015 Jun; 169(5):694-700. PubMed ID: 25818407
[TBL] [Abstract][Full Text] [Related]
25. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
28. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
[TBL] [Abstract][Full Text] [Related]
29. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
30. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
31. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
[TBL] [Abstract][Full Text] [Related]
32. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
33. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson RA; Mandrekar SJ; Huebner LJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Voso MT; Klisovic RB; Galinsky I; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Döhner H; Stone RM
Leukemia; 2021 Sep; 35(9):2539-2551. PubMed ID: 33654204
[TBL] [Abstract][Full Text] [Related]
34. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
[TBL] [Abstract][Full Text] [Related]
35. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
37. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
[TBL] [Abstract][Full Text] [Related]
38. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
[TBL] [Abstract][Full Text] [Related]
40. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
